ClinicalTrials.Veeva

Menu

Lesion Contiguity in Very High Power-short Duration Ablation

U

University of Barcelona

Status

Unknown

Conditions

Atrial Fibrillation

Study type

Observational

Funder types

Other

Identifiers

NCT05368610
QDOT-MRI

Details and patient eligibility

About

This observational trial investigates the effect of very high power-short duration radiofrequency ablation on lesion contiguity as assessed by late gadolinium enhancement cardiovascular magnetic resonance (LGE-CMR). Patients with paroxysmal or early persistent atrial fibrillation (AF) scheduled for pulmonary vein isolation (PVI) undergo point-by-point ablation using the QDOT micro catheter applying Qmode+ (90W over 4 seconds). All patients receive an LGE-CMR 3 months after the procedure for ablation lesion assessment. Contiguity of LGE-CMR-detected ablation lesions will be compared with a matched control group of patients that have undergone PVI accomplished by ablation index-guided ablation with 40 W following the CLOSE protocol.

Enrollment

128 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • paroxysmal or early persistent (max. 3 months) atrial fibrillation
  • scheduled for PVI-only catheter ablation

Exclusion criteria

  • long-standing persistent atrial fibrillation
  • previous left atrial ablation
  • claustrophobia preventing CMR
  • sever renal insufficiency (GFR >30 ml/min)
  • gadolinium contrast allergy
  • presence of implantable devices not compatible with magnetic resonance
  • pregnancy and lactation

Trial design

128 participants in 2 patient groups

Very high power-short duration ablation
Description:
PVI performed by point-by-point very high power-short duration radiofrequency ablation (QDOT-micro catheter, Biosense Webster; Qmode+; 90 W; 4 sec; target intertag distances: posterior wall 4 mm, proximity of the esophagus 5 mm, all other 3 mm)
Matched control group conventional ablation
Description:
PVI performed by conventional point-by-point radiofrequency ablation (40 W; ablation index-guided: posterior wall 350, other 450; target intertag distance 3.0 - 5.0 mm)

Trial contacts and locations

1

Loading...

Central trial contact

Till F. Althoff, M.D.; Lluis Mont, M.D., Ph.D.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems